Moderator:

Christopher E. Walsh, MD, PhD
Associate Professor of Medicine, Division of Hematology & Medical Oncology
Icahn School of Medicine at Mount Sinai
Director, Hemophilia Treatment Center, Mount Sinai Hospital, NY

 

Speakers:

Cécile Denis, Ph.D.
Director of Research French National Institute of Health and Medical Research (INSERM) Le Kremlin-Bicêtre, Cedex, France

Peter J. Lenting, Ph.D.
Director of Research French National Institute of Health and Medical Research (INSERM) Le Kremlin-Bicêtre, Cedex, France

Veronica H. Flood, MD
Associate Medical Dir./Investigator Associate Prof. of Pediatrics,
Medical College of WI Div. of Hematology/Oncology CCBD and
Versiti Blood Research Institute, Milwaukee, WI

Angela C. Weyand, MD
Clinical Assistant Professor, Dept of Pediatrics and Communicable Diseases University of Michigan Hemophilia and Coagulation Disorders, Ann Arbor, MI

Nikole Scappe
Education Specialist, National Bleeding Disorders Foundation

 

After completing this activity, the participant should be better able to:

  • Describe diagnostic pathways for evaluation of von Willebrand disease.
  • Discuss diagnostic thresholds and subtype classification of VWD.
  • Discuss utility of prophylaxis for patients with severe bleeding in VWD.
  • Examine emerging scientific advances that might lead to novel therapeutics for patients with von Willebrand disease.